LAX.SH
JUBILANT PHARMOVA LTD·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
880.35
+1.06%52W Range
Market Cap
₹14,022.32 Cr
Traded: ₹20.20 Cr (0.14%) 0.0x
Free Float: ₹3,225.13 Cr (0.63% of FF traded)
Volume · 60D trend
2.29 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +10.0% | +4.0% | +6.0% | -- | -- | Stable |
| Sales | +4.0% | +6.0% | +10.0% | -- | +14.0% | Accelerating |
| Profit | +1.0% | -13.0% | +47.0% | -- | -22.0% | Stable |
| Return | +12.0% | +4.0% | +42.0% | -6.0% | -- | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,229 | 2,290 | 2,122 | 1,966 | 1,901 | 1,929 | 1,822 | 1,752 | 1,732 | 1,759 | 1,677 | 1,680 | 1,587 | 1,678 | 1,552 | 1,600 |
| Expenses | 1,981 | 1,951 | 1,833 | 1,625 | 1,611 | 1,584 | 1,535 | 1,463 | 1,480 | 1,487 | 1,459 | 1,438 | 1,419 | 1,459 | 1,408 | 1,384 |
| Operating Profit | 248 | 339 | 289 | 341 | 290 | 345 | 287 | 289 | 252 | 271 | 218 | 242 | 168 | 219 | 144 | 216 |
| OPM % | 11.0% | 15.0% | 14.0% | 17.0% | 15.0% | 18.0% | 16.0% | 17.0% | 15.0% | 15.0% | 13.0% | 14.0% | 11.0% | 13.0% | 9.0% | 14.0% |
| Other Income | 20 | 10 | -19 | 4 | 12 | 9 | -10 | 8 | 410 | -151 | 49 | 19 | 9 | 21 | 10 | -44 |
| Interest | 54 | 56 | 56 | 50 | 49 | 53 | 56 | 61 | 71 | 73 | 71 | 66 | 62 | 56 | 51 | 42 |
| Depreciation | 127 | 117 | 121 | 105 | 98 | 95 | 91 | 91 | 91 | 101 | 95 | 97 | 90 | 271 | 94 | 94 |
| Profit Before Tax | 86 | 176 | 93 | 190 | 154 | 206 | 130 | 144 | 500 | -54 | 101 | 98 | 25 | -86 | 9 | 36 |
| Tax % | 35.0% | 32.0% | 40.0% | 37.0% | 34.0% | 27.0% | 23.0% | 29.0% | 4.0% | 15.0% | 34.0% | 37.0% | 76.0% | 16.0% | 285.0% | 87.0% |
| Net Profit | 56 | 119 | 56 | 120 | 102 | 151 | 101 | 102 | 482 | -62 | 66 | 62 | 6 | -100 | -16 | 5 |
| Exceptional Items | 0 | -14 | -40 | -6 | 0 | -3 | -19 | -14 | 396 | -169 | 0 | 0 | 0 | 0 | 0 | -57 |
| EPS (Rs) | 3.5 | 7.5 | 3.5 | 7.5 | 6.5 | 9.6 | 6.3 | 6.5 | 30.3 | -3.7 | 4.2 | 3.9 | 0.4 | -6.2 | -1.0 | 0.3 |
| Sales Growth (YoY) | -- | 18.7% | 16.5% | 12.2% | 9.8% | 9.7% | 8.6% | 4.3% | 9.1% | 4.8% | 8.0% | 5.0% | 9.3% | 9.8% | -- | -- |
| Sales Growth (QoQ) | -- | 7.9% | 7.9% | 3.4% | -1.4% | 5.9% | 4.0% | 1.1% | -1.5% | 4.9% | -0.2% | 5.9% | -5.4% | 8.1% | -3.0% | -- |
| OP Growth (YoY) | -14.5% | -1.7% | 0.7% | 18.0% | 15.1% | 27.3% | 31.7% | 19.4% | 50.0% | 23.7% | 51.4% | 12.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | -26.8% | 17.3% | -15.2% | 17.6% | -15.9% | 20.2% | -0.7% | 14.7% | -7.0% | 24.3% | -9.9% | 44.0% | -23.3% | 52.1% | -33.3% | -- |
| Profit Growth (YoY) | -- | -17.0% | -31.0% | 10.0% | -4.0% | 16453.0% | 72.0% | 81.0% | 1570.0% | 99.0% | 528.0% | 306.0% | -86.0% | -264.0% | -131.0% | -121.0% |
| EPS Growth (YoY) | -- | -22.2% | -44.5% | 17.1% | -78.7% | 362.0% | 51.1% | 64.5% | 7465.0% | 40.2% | 527.5% | 1052.9% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 113.7% | -53.5% | 16.9% | -33.0% | 52.3% | -1.9% | -78.7% | 922.3% | -187.8% | 6.9% | 880.0% | 106.5% | -527.5% | -388.2% | -- |
| OP Margin | -- | 14.8% | 13.6% | 17.3% | 15.3% | 17.9% | 15.8% | 16.5% | 14.6% | 15.4% | 13.0% | 14.4% | 10.6% | 13.1% | 9.3% | 13.5% |
| Net Margin | -- | 5.2% | 2.6% | 6.1% | 5.4% | 7.8% | 5.5% | 5.8% | 27.8% | -3.5% | 3.9% | 3.7% | 0.4% | -6.0% | -1.0% | 0.3% |
| Material Cost % | 33.6% | 31.1% | 33.8% | 30.3% | 32.5% | 32.5% | 31.5% | 31.7% | 32.4% | 30.0% | 31.9% | 33.2% | 32.8% | 31.6% | 30.8% | 30.2% |
| Employee Cost % | 33.8% | 33.5% | 33.3% | 32.4% | 31.1% | 30.6% | 30.8% | 32.2% | 31.9% | 31.6% | 34.7% | 31.6% | 34.5% | 31.8% | 36.6% | 33.4% |
| P/S | 1.63 | 1.85 | 2.04 | 1.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 39.82 | 38.48 | 37.25 | 28.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.98 | 2.16 | 2.44 | 2.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50USFDA Approval for Line 3, Contract manufacturing facility, Spokane, USA
Outcome of Postal Ballot
Scrutinizer''s Report
Newspaper Publications
Un-audited Financial Results for the Quarter ended June 30, 2026
Press Release and presentation
outcome of Board meeting
Pursuant to Regulations 30 & 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Annual Report along with Notice of AGM ....
Pursuant to Regulations 30 & 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Annual Report along with Notice of AGM ....
Please find enclosed herewith the Business Responsibility and Sustainability Report for the financial year 2025-26
Please find attached herewith the Notice of 48th Annual General Meeting alongwith the Annual Report for the Financial Year 2025-26. The 48th AGM of the Company will be held on Wednesday, ....
Newspaper publication - Dispatch of Postal Ballot
Notice of Postal Ballot dated July 18, 2026
Approval for Grant of Stock Options/RSUs/PSUs
Rectification order from the Income Tax Department
Compliances under Regulation 74 (5) of SEBI (DP) Regulation, 2018, for the quarter ended on June 30, 2026
newspaper publication
Receipt of Rectification order
Intimation for the closure of trading window for the quarter ending on June 30, 2026.
Tentative approval for Panto-prazole Sodium DR
Rectification Order in the matter of Jubilant Generics Limited, Wholly owned step down subsidiary
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 19, 2026 for HSB Trustee Company ....
Completion of USFDA inspection
USFDA update
Annual Secretarial Compliance Report
Earnings Call Transcript
Newspaper Publication
Earnings Call
Tax Demand order received by company''s step down subsidiary
Change in CFO
Change in CFO
Press Release and Presentation On Financials
Appointment of MD and JMD
Audited Financial Results for the quarter and year ended March 31, 2026
Outcome of Board Meeting held on May 22, 2026
Record Date
Board approves Final Dividend
Investor Meet
Intimation of Investor Meet
Newspaper Publication
Investor Meet
Investor Meet
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve the Audited Standalone and ....
Certificate under Reg 74(5) of SEBI(DP) Regulations, 2018
Newspaper Publication relating to notice to shareholders
Submission of communication to shareholders relating to notice of transfer of Equity shares/ Dividend to IEPF Authority
Intimation of Closure of Trading Window
Newspaper Advertisement relating to Notice of Shareholders
USFDA Communication Montreal, Canada
Newspaper Publication
Annual Reports
15Credit Ratings
6Concalls
44Feb 2026
28 Feb 2026Oct 2025
31 Oct 2025Jul 2025
31 Jul 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Jan 2025
31 Jan 2025Oct 2024
31 Oct 2024Jul 2024
31 Jul 2024May 2024
31 May 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Oct 2023
31 Oct 2023Jul 2023
31 Jul 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Mar 2022
31 Mar 2022Jan 2022
31 Jan 2022Jul 2021
31 Jul 2021Jun 2021
30 Jun 2021Jan 2021
31 Jan 2021Nov 2020
30 Nov 2020Sep 2020
30 Sept 2020Jun 2020
30 Jun 2020Jan 2020
31 Jan 2020Oct 2019
31 Oct 2019Jul 2019
31 Jul 2019May 2019
31 May 2019Feb 2019
28 Feb 2019Oct 2018
31 Oct 2018Jul 2018
31 Jul 2018Jun 2018
30 Jun 2018May 2018
31 May 2018Jan 2018
31 Jan 2018Oct 2017
31 Oct 2017Aug 2017
31 Aug 2017May 2017
31 May 2017Jan 2017
31 Jan 2017Oct 2016
31 Oct 2016Jul 2016
31 Jul 2016May 2016
31 May 2016Jan 2016
31 Jan 2016Held by ETFs
13 ETFs hold jublpharma · sorted by weight
Held by Mutual Funds
34 schemes hold jublpharma · sorted by weight